Artiva Biotherapeutics (ARTV) financial statements
Artiva Biotherapeutics reported revenue of $0 in fiscal 2025, down 99.2% a year over 1 years.
Net income was -$84M.
Free cash flow was -$79M.
The diluted share count rose 2945% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Artiva Biotherapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $33M | $251,000 | $0 |
| Research and development | $50M | $50M | $70M |
| Selling, general and admin | $14M | $17M | $20M |
| Operating income | -$31M | -$67M | -$90M |
| Pre-tax income | -$29M | -$65M | $84M |
| Income tax | $72,000 | $0 | $0 |
| Net income | -$29M | -$65M | -$84M |
| EPS (diluted) | -$35.78 | -$5.81 | -$3.43 |
| Diluted shares | 1M | 11M | 24M |
| Operating margin | -93.2% | -26805.6% | — |
| Net margin | -87.2% | -26045.0% | — |
Balance sheet
Fiscal years, from Artiva Biotherapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $77M | $185M | $108M |
| Receivables | $1M | $0 | — |
| Total current assets | $80M | $189M | $113M |
| Property, plant and equipment | $8M | $6M | $7M |
| Total assets | $105M | $210M | $131M |
| Total current liabilities | $12M | $12M | $13M |
| Total liabilities | $51M | $23M | $21M |
| Shareholders' equity | -$162M | $187M | $110M |
| Net debt | -$54M | -$40M | -$27M |
Cash flow
Fiscal years, from Artiva Biotherapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -$47M | -$55M | -$77M |
| Capital spending | $3M | $642,000 | $3M |
| Free cash flow | -$51M | -$56M | -$79M |
| Stock-based compensation | $7M | $7M | $7M |
| Free cash flow margin | -154.0% | -22180.9% | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ARTV.
Open ARTV in InvestinglyQuestions
What was Artiva Biotherapeutics's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
How much free cash flow does Artiva Biotherapeutics generate?
-$79M in fiscal 2025 (operating cash flow minus capital spending).
From Artiva Biotherapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.